Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + hepatitis B vaccine + Haemophilus influenzae type b vaccine
- Development stage
- Unknown
- Lead developer
- University of Oxford
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Diphtheria toxoid + tetanus toxoid + hepatitis B vaccine + Haemophilus influenzae type b vaccine is a quadrivalent combination vaccine (DT-HBV-Hib) designed to stimulate protective immune responses against diphtheria, tetanus, hepatitis B virus infection, and Haemophilus influenzae type b (Hib) disease. It comprises four active immunological components: diphtheria toxoid, tetanus toxoid, a hepatitis B surface antigen (HBsAg)-based hepatitis B vaccine, and a Haemophilus influenzae type b (Hib) conjugate antigen. The vaccine acts by stimulating the immune system's B and T cells to induce antigen-specific antibody production against the respective pathogens. It has been studied by the University of Oxford (Oxford Vaccine Group) in a randomized, open-label infant immunization schedule trial in Kathmandu, Nepal, to evaluate optimal timing of infant vaccination schedules.
- Other names
- DT-HBV-Hib vaccineDT-HepB-Hib vaccinequadrivalent DT-HBV-Hib vaccinediphtheria, tetanus, hepatitis B, and Haemophilus influenzae type b vaccine
02
Targets
B-cell receptor specific for Haemophilus influenzae type b capsular polysaccharideTCR (T cell antigen receptor complex)BCR-DT (B-cell receptor specific for diphtheria toxoid)TT-BCR (Tetanus toxoid-specific B-cell receptor)HBsAg-specific BCR (HBsAg-specific B-cell receptor)
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + hepatitis B vaccine + Haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + hepatitis B vaccine + Haemophilus influenzae type b vaccine.